Organized by Sizun Jiang, Beth Israel Deaconess Medical Center
Co-organized by LUMICKS
Join us for a dynamic one-day symposium that will bring together leading scientists at the forefront of immunotherapy innovation. This event will explore groundbreaking advancements across several key areas of immunotherapy research and development.
Through a series of expert-led presentations and discussions, participants will gain insights into cutting-edge breakthroughs, including:
-
Novel CAR-T cell strategies for cancer
-
Advances in cell engagers in oncology
-
Cell therapy for autoimmune diseases
-
Novel mechanisms and modalities in immunotherapy
-
Next-Generation technologies for immunotherapy development
This symposium will offer a unique platform for networking, fostering collaboration, and sharing knowledge that will drive the future of immunotherapy. Whether you are an academic, clinician, or industry professional, this event is a must-attend opportunity to stay at the cutting edge of this rapidly evolving field.
Date: 13 March 2025
Location: Pechet Family Conference Room at The Joseph B Martin Conference Center, Harvard Medical School
This event is in the past, but please let us know if you’re interested in the next edition!
Speakers and hosts
William Sellers, M.D.
Broad Institute and Dana-Farber Cancer Institute
Mark Leick, M.D.
Massachusetts General Hospital
Sizun Jiang, Ph.D.
Beth Israel Deaconess Medical Center
Alex Shalek, Ph.D.
MIT
Yufei Wang, Ph.D.
Dana-Farber Cancer Institute
Shira Segal
LUMICKS
Kai Wucherpfennig, M.D. Ph.D
Dana-Farber Cancer Institute
Elisa Bergaggio, Ph.D.
Boston Children’s Hospital
Margaux Audett, Ph.D
Orbital Therapeutics
Eric Smith, M.D. Ph.D.
IMPACT² at Dana-Farber Cancer Institute
Anusuya Ramasubramanian, Ph.D.
IMPACT² at Dana-Farber Cancer Institute
Baochun Zhang, M.D. Ph.D.
Dana-Farber Cancer Institute
Agenda
|
8:00 – 8:55 |
Registration and breakfast |
|
8:55 – 9:10 |
Welcome Introduction |
|
9:10-9:50 |
William Sellers, M.D. – “The Development of Biparatopic Antibodies Targeting FGFR2 in Cancer” |
|
9:50-10:30 |
Yufei Wang, Ph.D. – “Design of CAR-T Cell Therapy to Achieve Renal Cell Carcinoma (RCC) Cures” |
|
10:30-11:00 |
Mark Leick, M.D. – “Understanding drivers of CAR-T response and toxicity” |
|
11:00-11:30 |
Margaux Audett, Ph.D. – “Improving the Binder Selection Process for In Vivo CAR Therapies with Cell Avidity” |
|
11:30-12:30 |
Lunch |
|
12:30-1:00pm |
Shira Segal – “Cell Avidity Analysis: a novel assay to understand mechanism of action of novel Immunotherapeutics” |
|
1:00-1:40 |
Anusuya Ramasubramanian, Ph.D. & Eric Smith, M.D. Ph.D. – “Harnessing facile platforms for screening immunotherapy libraries to engineer effective & safe cell therapies” |
|
1:40-2:10 |
Elisa Bergaggio, Ph.D. – “ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells” |
|
2:10-2:40 |
Baochun Zhang, M.D. PhD – “Multiantigen-targeted cytotoxic CD4+ T cells for cancer therapy.” |
|
2:40-3:00 |
Break |
|
3:00-3:30 |
Kai Wucherpfennig, M.D. Ph.D – “Epigenetic mechanisms of resistance to cancer immunotherapy” |
|
3:30-4:00 |
Sizun Jiang, Ph.D. – “Dissecting the Tumor Microenvironment In Situ“ |
|
4:00-4:40 |
Alex Shalek, Ph.D. – “Characterizing Cell-Intrinsic and Microenvironmental Drivers of Cell State, Plasticity, and Drug Response in Cancer” |
|
4:40-5:00 |
Closing Remarks |
|
5:30-7:00 |
Happy Hour with Short Talk Sessions – Offsite |
